Multiple Myeloma – Access & Reimbursement – Detailed, Expanded Analysis (US)


Successive label expansions in the multiple myeloma treatment landscape are driving significant commercial reward for some well-entrenched current therapies. With Celgene’s Revlimid and Janssen / Takeda Pharmaceutical’s Velcade as cornerstones, emerging therapies such as Bluebird Bio / Celgene’s bb2121 and GlaxoSmithKline’s GSK2857916 are pursuing initial approvals for the treatment of multiple myeloma and can expect premium pricing. Further, as a result of expected label expansions of current therapies, multiple myeloma regimens will increasingly include high-priced therapies. Understanding the market access drivers that are important to payers and oncologists will be essential in maximizing these therapies’ uptake.


  • What roles do key brands such as Darzalex and Empliciti play in the treatment of multiple myeloma in the United States, and in what treatment settings are they typically prescribed?
  • How broadly do MCOs cover multiple myeloma agents on their formularies, particularly for the regimens that include both oral and IV agents? What kind of restrictions do they apply to control usage?
  • Do payers believe that the efficacy of the various therapies justifies their cost, and which drug do they think performs the best on clinical and other attributes?
  • What are physicians’ views on emerging therapies such as bb2121 and GSK2857916, as well as the subcutaneous formulation of Darzalex? How do clinicians expect their prescribing to change, and what factors, if any, will drive these changes?


United States


Survey of 100 hematologist-oncologists in the United States Survey of 32 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs)


Current therapies: Darzalex, Empliciti, Kyprolis, Ninlaro, Pomalyst, Revlimid, Velcade

Emerging therapies: bb2121, GSK2857916, subcutaneous Darzalex


  • Reimbursement and contracting
  • Access and prescribing
  • Special topics
  • Opportunities and challenges for emerging therapies.


U.S. Access & Reimbursement provides in-depth insight on the impact of payer policy on prescribing behavior so that clients can build their market access strategy and optimize their brand positioning. This analysis of primary market research with physician specialists and U.S. payers helps clients stay up-to-date on restriction policies, gauge payer and prescriber attitudes toward specific therapies, identify opportunities where brands can capture patient share through market access, and maximize opportunities for emerging therapies by learning how previous brands gained favorable reimbursement or why they stumbled.

launch Related Market Assessment Reports